COMy 2022 | Unmet needs in Waldenström’s macroglobulinemia
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses unmet needs in Waldenström’s macroglobulinemia (WM). Dr Treon first addresses the challenge of approaching patients who progress after receiving a Bruton’s tyrosine kinase (BTK) inhibitor, and further highlights the promise of non-covalent BTK inhibitors, such as pirtobrutinib. Dr Treon then comments on the high rate of activity observed in venetoclax as well as ibrutinib plus ulocuplumab, and the ongoing challenge of treating patients with MYD88 wild-type disease or CXCR4 mutation. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Research support, consulting and/or honoraria received from: Abbvie/Pharmacyclics, Beigene, BMS, Eli Lilly, Janssen Pharmaceuticals, X4 Pharmaceuticals. IP assigned to DFCI for MYD88, CXCR4, and IRAK and HCK and other inhibitors.
